The Journal holds the evidence library — 1,500-word trial-cited explainers. The Blog is its faster sibling: market-watch posts, offer teardowns, and pricing-pattern analyses, held to the same honesty rules (verified figures only, claims attributed, disclosure on every commercial page) at shorter length.

Latest from the market desk

Dated articles generated from the price dataset; every figure carries the day it was read on the provider’s page.

Posts

Changelog · 2026-08-26

August 2026 updates: Foundayo, the Bridge, and a bigger tracker

Orforglipron’s reported approval, the new Medicare $50 lane, seven U.S. News-rated platforms added — what changed and exactly what we updated.

Market watch

Q3 2026: where everything stands

Shortage aftermath, the channel war’s repricing, partnership churn, pipeline milestones, and the first generics.

Published 2026-08-20
Market watch

“Cheapest compounded tirzepatide online”: teardown

What the cheapest-offer search actually surfaces, and how the teaser mechanics work underneath.

Updated 2026-08-20

How the Blog differs from the Journal

Journal pieces are evidence files — built on named trials and labels, meant to age slowly. Blog posts are timestamped reads on a moving market — meant to be checked against the ledger and its archive as prices drift. When a blog observation hardens into durable guidance, it graduates into the Journal.